Invitation - Presentation of Orexo's third quarter results 2014


Uppsala, Sweden – October 15, 2014 - On October 22 at 08:00 am, Orexo AB (publ)
will publish its report for the third quarter 2014.

Financial analysts and media are invited to participate in a telephone
conference, which will include a presentation of the third quarter results, at
1:30 pm CET (07:30 am EDT). The event will be hosted by Orexo's CEO and
President Nikolaj Sørensen and CFO Henrik Juuel. The general and financial
presentation will this time be followed by an update on the ISTART study results
presented by Chief Medical Officer Michael Sumner. The presentation will be held
in English.

The presentation can be followed live, or afterwards on www.orexo.com, where the
slides used in the presentation will be made available.

To participate in the telephone conference, please call:
SE: +46 8 519 993 59
UK: +44 203 194 0553
US: +1 855 269 2607

To view the presentation, please visit financialhearings.nu/141022/orexo.

For further information, please contact:
Beata Augenblick, Investor Relations
Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

About Orexo
Orexo is a specialty pharma company with commercial operations in the United
States and R&D in Sweden developing improved treatments using proprietary drug
delivery. The company is commercializing its proprietary product, ZUBSOLV®
sublingual tablets, for maintenance treatment of opioid dependence, in the
United States. The ZUBSOLV sublingual tablet is a novel formulation of
buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual
technologies. Orexo has a portfolio of two approved and revenue generating
products currently marketed under license in the US, EU and Japan. Orexo AB,
with its headquarters in Sweden, is listed on Nasdaq Stockholm Exchange and its
American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S.
under the symbol, “ORXOY”. The largest shareholders are Novo A/S and HealthCap.

For information about Orexo, please visit www.orexo.com

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act. The information was submitted for publication
at 5:15 pm CET on October 15, 2014.

Attachments

10150102.pdf